Camp4 Therapeutics Files S-1/A for IPO
Ticker: CAMP · Form: S-1/A · Filed: Oct 7, 2024 · CIK: 1736730
Sentiment: neutral
Topics: ipo, sec-filing, biotech
TL;DR
Camp4 IPO filing updated. Get ready.
AI Summary
Camp4 Therapeutics Corp. filed an S-1/A amendment on October 7, 2024, for its initial public offering. The company, located at One Kendall Square in Cambridge, MA, is seeking to register an unspecified number of shares. This filing is an amendment to a previous registration statement, indicating ongoing preparations for its IPO.
Why It Matters
This S-1/A filing signifies Camp4 Therapeutics' continued progress towards becoming a publicly traded company, which could bring new investment and development opportunities to its therapeutic pipeline.
Risk Assessment
Risk Level: medium — As a pre-IPO company, Camp4 Therapeutics faces inherent risks associated with market conditions, regulatory approvals, and the success of its novel therapeutic approaches.
Key Numbers
- 333-282241 — SEC File Number (Identifies this specific registration statement with the SEC.)
- 0001736730 — Central Index Key (Unique identifier for Camp4 Therapeutics in SEC filings.)
Key Players & Entities
- Camp4 Therapeutics Corp. (company) — Registrant
- October 7, 2024 (date) — Filing Date
- One Kendall Square, Cambridge, Massachusetts (location) — Principal Executive Offices
- Josh Mandel-Brehm (person) — Chief Executive Officer
FAQ
What is the purpose of this S-1/A filing?
This S-1/A filing is an amendment to Camp4 Therapeutics Corporation's initial registration statement (Form S-1) filed with the SEC, indicating updates or changes to their planned initial public offering.
When was this amendment filed?
This amendment was filed on October 7, 2024.
Where is Camp4 Therapeutics located?
Camp4 Therapeutics Corporation's principal executive offices are located at One Kendall Square, Building 1400 West, 3rd Floor, Cambridge, Massachusetts 02139.
Who is the CEO of Camp4 Therapeutics?
The Chief Executive Officer of Camp4 Therapeutics is Josh Mandel-Brehm.
What is the company's primary industry?
Camp4 Therapeutics Corporation falls under the Standard Industrial Classification code 2834, which pertains to Pharmaceutical Preparations.
Filing Stats: 4,504 words · 18 min read · ~15 pages · Grade level 16 · Accepted 2024-10-07 06:03:51
Key Financial Figures
- $14.00 — ffering price is expected to be between $14.00 and $16.00 per share. Prior to this o
- $16.00 — ce is expected to be between $14.00 and $16.00 per share. Prior to this offering, th
Filing Documents
- tm2415452-13_s1a.htm (S-1/A) — 3851KB
- tm2415452d14_ex3-1.htm (EX-3.1) — 41KB
- tm2415452d14_ex3-2.htm (EX-3.2) — 75KB
- tm2415452d14_ex5-1.htm (EX-5.1) — 6KB
- tm2415452d14_ex10-5.htm (EX-10.5) — 88KB
- tm2415452d14_ex10-6.htm (EX-10.6) — 20KB
- tm2415452d14_ex10-7.htm (EX-10.7) — 21KB
- tm2415452d14_ex10-8.htm (EX-10.8) — 19KB
- tm2415452d14_ex10-9.htm (EX-10.9) — 51KB
- tm2415452d14_ex10-10.htm (EX-10.10) — 60KB
- tm2415452d14_ex10-12.htm (EX-10.12) — 52KB
- tm2415452d14_ex10-13.htm (EX-10.13) — 10KB
- tm2415452d14_ex10-16.htm (EX-10.16) — 27KB
- tm2415452d14_ex23-1.htm (EX-23.1) — 2KB
- tm2415452d14_ex-filingfees.htm (EX-FILING FEES) — 15KB
- lg_camp4-4c.jpg (GRAPHIC) — 22KB
- ph_identify-4c.jpg (GRAPHIC) — 111KB
- fc_ourpipeline-4c.jpg (GRAPHIC) — 53KB
- ph_geneexpression-4c.jpg (GRAPHIC) — 78KB
- bc_functionaldisorder-4c.jpg (GRAPHIC) — 39KB
- ph_sodiumacetate-4c.jpg (GRAPHIC) — 58KB
- pc_ucdpatient-4c.jpg (GRAPHIC) — 50KB
- bc_concentration-4c.jpg (GRAPHIC) — 94KB
- lc_ureaproduction-4clr.jpg (GRAPHIC) — 55KB
- lc_ammonialevel-4c.jpg (GRAPHIC) — 95KB
- lc_ammoniaureagen-4clr.jpg (GRAPHIC) — 52KB
- bc_ucdmrna-4clr.jpg (GRAPHIC) — 51KB
- lc_ureagenesisauc-4c.jpg (GRAPHIC) — 46KB
- fc_clinicaltrialdesign-4c.jpg (GRAPHIC) — 64KB
- lc_syngap1brainsofmice-4clr.jpg (GRAPHIC) — 58KB
- lc_humanneurons-4c.jpg (GRAPHIC) — 55KB
- tm2415452d14_ex5-1img001.jpg (GRAPHIC) — 3KB
- 0001104659-24-106393.txt ( ) — 5684KB
Risk factors
Risk factors 15 Special Note Regarding Forward-Looking Statements 82 Market and industry data 84
Use of proceeds
Use of proceeds 85 Dividend policy 87 Capitalization 88
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 93
Business
Business 111 Management 157 Executive and director compensation 166 Certain relationships and related party transactions 179 Principal stockholders 183
Description of capital stock
Description of capital stock 186 S hares Eligible for Future Sale 191 Certain Material U.S. Federal Income Tax Consequences to Non U.S. Holders 194
Underwriting
Underwriting 198 Legal matters 210 Experts 210 Where You Can Find More Information 210 Index to consolidated financial statements F-1 Neither we nor the underwriters have authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any free writing prospectus prepared by or on behalf of us or to which we have referred you. We and the underwriters take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may provide you. We and the underwriters are not making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information contained in this prospectus is accurate only as of the date on the front cover of this prospectus, regardless of the time of delivery of this prospectus or of any sale of our common stock. Our business, financial condition, results of operations and prospects may have changed since that date. For investors outside of the United States: neither we nor any of the underwriters have done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than the United States. Persons outside of the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of common stock and the distribution of this prospectus outside of the United States. TABLE OF CONTENTS P ROSPECTUS SUMMARY This summary highlights, and is qualified in its entirety by, information contained elsewhere in this prospectus. This summary does not contain all of the information you should consider before investing in our common stock. You should read this entire prospectus carefully, especially the sections titled "Risk factors," "Business," and "Management's discussion and analys